Testing a new cancer drug combined with standard treatments for B-cell lymphoma

Plain-English translation of NCT07081022 on ClinicalTrials.gov ↗ · Source last updated August 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called JS203 combined with standard cancer treatments for people with B-cell lymphoma — a cancer of immune cells. Researchers want to see if adding this medication to treatments already used for lymphoma helps patients respond better. The study includes different groups based on the type of lymphoma and whether it's newly diagnosed or has come back after previous treatment.

Current treatments help some patients, but many people with B-cell lymphoma either don't respond well or see their cancer return. This trial exists to find out whether this medication can improve how well existing treatments work and help more patients achieve remission.

Do you qualify?

You likely qualify if…

you are between 18 and 80 years old
you have been diagnosed with B-cell non-Hodgkin's lymphoma confirmed by a biopsy
you have at least one tumor that can be measured on imaging
you have acceptable organ function (healthy kidneys, liver, heart, and blood counts)
you are in good enough health to handle cancer treatment (your doctor rates your overall condition as 0–2 on a standard activity scale)

You likely don't qualify if…

you have had a severe allergic reaction to monoclonal antibody therapy or similar drugs in the past
you have received previous treatment with a CD20-CD3 bispecific antibody
you have had a stem cell or organ transplant
you have a history of autoimmune disease, macrophage activation syndrome, or progressive multifocal leukoencephalopathy
you have or are suspected of having lymphoma in your central nervous system (brain or spinal cord), or you have fluid around your lungs, heart, or belly that needs to be drained

What participation looks like

Depending on your type of lymphoma and whether it's newly diagnosed or returning, you'll receive the new medication JS203 combined with one of several standard cancer drug regimens. You'll visit the clinic regularly for infusions, blood tests, and imaging scans to check how well the treatment is working. The trial involves about 180 participants total across different lymphoma subtypes, and your specific treatment schedule will depend on which group you join.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Trial locations(1 site)

China

Beijing Cancer Hospital, Beijing, Beijing Municipality